Interleukin-12: Clinical usage and molecular markers of cancer susceptibility

Growth Factors

Volumn 30, Issue 3, 2012, Pages 176-191

  Yuzhalin, Arseniy E ^a,b   Kutikhin, Anton G ^b  

^a KEMEROVO STATE UNIVERSITY   (Russian Federation)

^b KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cancer; Carcinogenesis; IL 12; Interleukin 12; SNP

Indexed keywords

ALBINTERFERON ALPHA2B; BEVACIZUMAB; CANCER VACCINE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 21; INTERLEUKIN 7; MELAN A; MESSENGER RNA; MOLECULAR MARKER; RECOMBINANT INTERLEUKIN 12; RITUXIMAB; SORAFENIB; STAT3 PROTEIN; STAT4 PROTEIN; SUNITINIB; TEMSIROLIMUS; TOLL LIKE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; BIOLOGICAL ACTIVITY; BRAIN TUMOR; BREAST CARCINOMA; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DEPRESSION; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; GASTROINTESTINAL CARCINOMA; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEAD AND NECK CANCER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HYPERPLASIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; METASTATIC MELANOMA; NASOPHARYNX CARCINOMA; NAUSEA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; ORAL MUCOSITIS; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STOMACH ULCER; T CELL LYMPHOMA; TUMOR CELL; TUMOR MICROENVIRONMENT; UNTRANSLATED REGION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VOMITING;

ANIMALS; BIOLOGICAL MARKERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; MICE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84861410440     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.678843     Document Type: Article

References (127)

1. Abbas AK, Lichtman AH, Pillai S. 2011. Cellular and molecular immunology. Philadelphia, PA: Elsevier.
2. Acquaviva J, Chen X, Ren R. 2008. IRF-4 functions as a tumor suppressor in early B-cell development. Blood 112(9): 3798-3806.
3. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. 2004. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma ormalignant melanoma. J Clin Oncol 22:2891-2900.
4. Aldred MA, Eng C. 2006. SNP'ing at nasopharyngeal cancer susceptibility: For whom the bell TOLLs. Cancer Biol Ther 5: 1292-1293.
5. Ansell SM,Witzig TE, Kurtin PJ, Sloan JA, JelinekDF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99(1):67-74.
6. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy- review of a new approach. Pharmacol Rev 55(2):241-269.
7. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, EdingtonHD, Garzone PD,Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3(3):409-417.
8. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4(1):75-85.
9. Becskei A, Grusby MJ. 2007. Contribution of IL-12R mediated feedback loop to Th1 cell differentiation. FEBS Lett 581(27): 5199-5206.
10. Ben Chaaben A, Busson M, Douik H, Boukouaci W, Mamoghli T, Chaouch L, Harzallah L, Dorra S, Fortier C, Ghanem A, Charron D, Krishnamoorthy R, Guemira F, Tamouza R. 2011. Association of IL-12p40 1188 A/C polymorphism with nasopharyngeal cancer risk and tumor extension. Tissue Antigens 78(2):148-151.
11. Berger FG. 2004. The interleukin-6 gene: A susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat 88(3):281-285.
12. Beyer M, Schultze JL. 2006. Regulatory T cells in cancer. Blood 108:804-811.
13. Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G. 2000. Ability of systemic interleukin-12 to hamper progressive stages of mammary arcinogenesis in HER2/neu transgenic mice. Cancer Res 60(2):359-364.
14. Bondy GS, Pestka JJ. 2000. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev 3:109-143.
15. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A,Wang A, Clarke R. 2005. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26(9):1527-1535.
16. Bowie ML, Ibarra C, Seewalt VL. 2008. IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: A model for early basal-type mammary carcinogenesis. Adv Exp Med Biol 617:367-374.
17. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. 1994. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 204(3): 1150-1157.
18. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178(4):1223-1230.
19. Castellarin M,Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. 2012. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22(2): 299-306.
20. Cavallo F, Quaglino E, Cifaldi L, Di Carlo E, André A, Bernabei P, Musiani P, Forni G, Calogero RA. 2001. Interleukin 12- activated lymphocytes influence tumor genetic programs. Cancer Res 61(8):3518-3523.
21. Cavanaugh VJ, Guidotti LG, Chisari FV. 1997. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 71(4):3236-3243.
22. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. 2007. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109(12):5439-5446.
23. Chatterjee N, Hartge P, Cerhan JR, Cozen W, Davis S, Ishibe N, Colt J, Goldin L, Severson RK. 2004. Risk of non-Hodgkin lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 13: 1415-1421.
24. Chen X, Han S,Wang S, Zhou X, Zhang M, Dong J, Shi X, Qian N, Wang X, Wei Q, Shen H, Hu Z. 2009. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res 15(1):400-405.
25. Davoodi-Semiromi A, Yang JJ, She JX. 2002. IL-12p40 is associated with type 1 diabetes in Caucasian-American families. Diabetes 51(7):2334-2336.
26. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. 2007. Interleukin-12: Biological properties and clinical application. Clin Cancer Res 13(16):4677-4685.
27. Delgado M, Ganea D. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin- 12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem 274(45):31930-31940.
28. Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM, Lai R. 2009. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 175(2):825-834.
29. Ekbom A, Helmick C, Zack M, Adami HO. 1990. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336(8711):357-359.
30. Fan H, Walters CS, Dunston GM, Tackey R. 2002. IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 19:126-137.
31. Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. 2008. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 58(12):3705-3709.
32. Fisher SG, Fisher RI. 2004. The epidemiology of non-Hodgkin's lymphoma. Oncogene 23(38):6524-6534.
33. Foukas LC, Panayotou G, Shepherd PR. 2004. Direct interaction of major histocompatibility complex class II-derived peptides with class Ia phosphoinositide 3-kinase results in dose-dependent stimulatory effects. J Biol Chem 279(9):7505-7511.
34. Friedmann E, Hauben E, Maylandt K, Schleeger S, Vreugde S, Lichtenthaler SF, Kuhn PH, Stauffer D, Rovelli G, Martoglio B. 2006. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8(8):843-848.
35. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. 1998. The interleukin-12/interleukin-12- receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 16:495-521.
36. Goldstein D, Laszlo J. 1988. The role of interferon in cancer therapy: A current perspective. CA Cancer J Clin 38(5): 258-277.
37. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. 2003. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21(13):2564-2573.
38. Gravisaco MJ, Mongini C, Alvarez E, Ruybal P, Escalada A, Sanchez-Lockhart M, Hajos S, Waldner C. 2003. IL-2, IL-10, IL-15 and TNF are key regulators of murine T-cell lymphoma growth. Int J Mol Med 12(4):627-632.
39. Guidotti LG, Guilhot S, Chisari FV. 1994. Interleukin-2 and alpha/ beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol 68(3):1265-1270.
40. Guo Q, Shen S, Li X, Tang K, ZhouW. 2011. Inflammatory factors promote the development of colorectal cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36(7):646-649.
41. Han SS, Cho EY, Lee TS, Kim JW, Park NH, Song YS, Kim JG, Lee HP, Kang SB. 2008. Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical cancer in Korean women. Eur J Obstet Gynecol Reprod Biol 140(1):71-75.
42. Hashmi MH, Van Veldhuizen PJ. 2010. Interleukin-21: Updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 10(5): 807-817.
43. Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. 2003. Human CD4 T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol 170(1):400-412.
44. Hill HC, Conway TF, Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62(24):7254-7263.
45. Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M, Chanock SJ, Zatonski W, Sobin LH, Lissowska J, Fraumeni JF, Jr, Chow WH. 2007. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 28(1):118-123.
46. Howell WM, Rose-Zerilli MJ. 2007. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137(1 Suppl): 194S-199S.
47. Howell WM, Turner SJ, Theaker JM, Bateman AC. 2003. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30(6):409-414.
48. Huang ZQ, Wang JL, Pan GG, Wei YS. 2011. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem 45(1-2):54-59.
49. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13(2):95-109.
50. Jakobisiak M, Golab J, LasekW. 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 22(2):99-108.
51. Jones EA, Pringle JH, Angel CA, Rees RC. 2002. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non- Hodgkin's lymphoma (NHL). Leuk Lymphoma 43(6): 1313-1321.
52. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M. 2002. Regression of cervical intraepithelial neoplasia and loss of human apillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Albert Einstein Cervix Dysplasia Clinical Consortium. Cancer Epidemiol Biomarkers Prev 11(5):483-488.
53. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L, Tosato G. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64(3):384-392.
54. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170(3):827-845.
55. Kordi Tamandani DM, Shekari M, Suri V. 2009. Interleukin-12 gene polymorphism and cervical cancer Risk. Am J Clin Oncol (Epub ahead of print).
56. Kornbluth A, Sachar DB. 2004. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99(7):1371-1385.
57. Kurzrock R. 1997. Cytokine deregulation in hematological malignancies: Clinical and biological implications. Clin Cancer Res 3(12 Pt 2):2581-2584.
58. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T. 2006. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 7(7):740-746.
59. Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, Moreno V. 2006. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed 5:15.
60. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S. 2006. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non- odgkin lymphoma. Blood 107(10):4101-4108.
61. Lee KM, Shen M, Chapman RS, Yeager M,Welch R, He X, Zheng T, Hosgood HD, Yang D, Berndt SI, Chanock S, Lan Q. 2007. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis 28(7):1437-1441.
62. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. 2003. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 24(3):81-90.
63. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. 2002. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8: 3686-3695.
64. Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, Liu J, Liu S, Ji G, Shi H, Shen H, Hu Z. 2011. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer 128(7):1692-1696.
65. Lowy DR, Schiller JT. 2006. Prophylactic human papillomavirus vaccines. J Clin Invest 116(5):1167-1173.
66. Ma X, Trinchieri G. 2001. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 79:55-92.
67. Mackall CL, Fry TJ, Gress RE. 2011. Harnessing the biology of IL- 7 for therapeutic application. Nat Rev Immunol 11(5):330-342.
68. Meyaard L, Hovenkamp E, Otto SA, Miedema F. 1996. IL-12- induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol 156: 2776-2782.
69. Ming J, Jiang G, Zhang Q, Qiu X, Wang E. 2012. Interleukin-7 upregulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer. Cancer Immunol Immunother 61(1): 79-88.
70. Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. 2009. Association of polymorphisms in regulatory regions of interleukin- 12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest 27(9):924-931.
71. Mitsuhashi M, Liu J, Cao S, Shi X, Ma X. 2004. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76(2):322-332.
72. Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Dabadghao P,Werther G, Tait BD, Harrison LC. 2001. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a negulatory IL12B allele. Nat Genet 27:218-221.
73. Morahan G, McKinnon E, Berry J, Browning B, Julier C, Pociot F, James I, Type I Diabetes Genetics Consortium. 2009. Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun 10(Suppl 1):S64-S68.
74. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. 2000. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8 T cells in melanoma patients receiving interleukin 12. Cancer Res 60(13): 3559-3568.
75. Motzer RJ, Bukowski RM. 2006. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24(35):5601-5608.
76. Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM. 2001. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21(4):257-263.
77. Murakami S, Okubo K, Tsuji Y, Sakata H, Hamada S, Hirayama R. 2004. Serum interleukin-12 levels in patients with gastric cancer. Surg Today 34(12):1014-1019.
78. Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M. 2008. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 181(10):6837-6842.
79. Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK. 2006. IL-12 GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in HER-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 29(1):10-20.
80. Nakahira M, Tomura M, Iwasaki M, Ahn HJ, Bian Y, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H. 2001. An absolute requirement for STAT4 and a role for IFN-gamma as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J Immunol 167(3):1306-1312.
81. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1195-1205.
82. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Johns A. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153(4):1697-1706.
83. Navaglia F, Basso D, Zambon CF, Ponzano E, Caenazzo L, Gallo N, Falda A, Belluco C, Fogar P, Greco E, Di Mario F, Rugge M, Plebani M. 2005. Interleukin 12 gene polymorphisms enhance gastric cancer risk in H. pylori infected individuals. J Med Genet 42:503-510.
84. Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, Yu MC. 2005. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 103(4):740-748.
85. Noguchi Y, Jungbluth A, Richards EC, Old LJ. 1996. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 93:11798-11801.
86. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. 2009. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 30(5):758-762.
87. Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE, 3rd.. 2004. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10(15):5027-5037.
88. Park JS, Cheong JY, Kang JK, Cho JH, Yu S, Shin HD, Park BL, Cho SW. 2007. Association of interleukin-12 gene polymorphism with persistence of hepatitis B virus infection and hepatocellular carcinoma. Korean J Gastroenterol 50(5): 313-318.
89. Parsonnet J. 1993. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 22:89-104.
90. Pathak S, Ma S, Trinh L, Eudy J,Wagner KU, Joshi SS, Lu R. 2011. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 6(7):e22628.
91. Peterson AC, Harlin H, Gajewski TF. 2003. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21(12):2342-2348.
92. Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE. 1999. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5(12):3983-3989.
93. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK. 2007. Polymorphisms in immune function genes and risk of non- Hodgkin lymphoma: Findings from the New South Wales non- Hodgkin Lymphoma Study. Carcinogenesis 28(3):704-712.
94. Qu Y, Taylor JL, Bose A, Storkus WJ. 2011. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)- 32. Cancer Gene Ther 18(9):663-673.
95. Rook AH,Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. 1999. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94(3):902-908.
96. Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71(6):862-873.
97. Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K, Kawano S, Chiba T. 2007. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: Comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol 22(5):729-737.
98. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. 2008. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44(12):1093-1099.
99. Sgadari C, Angiolillo AL, Tosato G. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferoninducible protein 10. Blood 87:3877-3882.
100. Sima X, Xu J, Li Q, Luo L, Liu J, You C. 2011. Gene-gene interactions between interleukin-12A and interleukin-12B with the risk of brain tumor. DNA Cell Biol 31(2):219-223.
101. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. 2011. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother 60(12):1775-1787.
102. Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gately MK. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87(17): 6808-6812.
103. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. 1994. Macrophages and angiogenesis. J Leukoc Biol 55(3): 410-422.
104. Takaoka A, Hayakawa S, Yanai H, StoiberD, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424(6948): 516-523.
105. Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. 2009. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115(4):859-868.
106. Ter-Minassian M,Wang Z, Asomaning K,Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. 2011. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis 32(8):1216-1222.
107. Trinchieri G. 1998. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 70:83-243.
108. Veltri S, Smith JW, 2nd.. 1996. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects. Stem Cells 14(2):164-176.
109. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87(8):581-586.
110. Wadler S, Levy D, Frederickson HL, Falkson CI,Wang Y,Weller E, Burk R, Ho G, Kadish AS, Eastern Cooperative Oncology Group. 2004. A phase II trial of interleukin-12 in patients with advanced cervical cancer: Clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92(3):957-964.
111. Waldmann TA. 2006. The biology of interleukin-2 and interleukin- 15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601.
112. Wang KS, Frank DA, Ritz J. 2000. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through upregulation of the interleukin-12 receptor and STAT4. Blood 95(10):3183-3190.
113. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N. 2006. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66(19):9771-9780.
114. Watkins SK, Egilmez NK, Suttles J, Stout RD. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumorinfiltrating macrophages in vitro and in vivo. J Immunol 178(3): 1357-1362.
115. Watkins SK, Li B, Richardson KS, Head K, Egilmez NK, Zeng Q, Suttles J, Stout RD. 2009. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur J Immunol 39(8): 2126-2135.
116. Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laiberte RJ, Sherman ML. 2003. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26:343-348.
117. Wei YS, Lan Y, Luo B, Lu D, Nong HB. 2009. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol Carcinog 48(8):751-757.
118. Xin Z, Sriram S. 1998. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol 89(1-2):206-212.
119. Yanagida T, Kato T, Igarashi O, Inoue T, Nariuchi H. 1994. Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol 152(10):4919-4928.
120. Ye ZB, Ma T, Li H, Jin XL, Xu HM. 2007. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13(11): 1747-1751.
121. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-gamma production. J Immunol 161(7):3400-3407.
122. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. 2004. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10(16):5432-5438.
123. Yu MC, Yuan JM. 2004. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72-S78.
124. Yuzhalin A. 2011. The role of interleukin DNA polymorphisms in gastric cancer. Hum Immunol. 72(11):1128-1136.
125. Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ. 2009. A novel functional polymorphism, 16974 A/C, in the interleukin-12-3' untranslated region is associated with risk of glioma. DNA Cell Biol 28(7):335-341.
126. Zhu Y, Michelle Luo T, Jobin C, Young HA. 2011. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 309(2): 119-127.
127. Van-Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher C, Cavers D, Coy P, Brigden ML. 1993. Macrophage-tumor cell associations: A factor in metastasis of breast cancer? J Leukoc Biol 54:360-362.